home / stock / ngenf / ngenf news

NGENF News and Press, NervGen Pharma Corp From 09/13/21

Stock Information
Company Name: NervGen Pharma Corp
Stock Symbol: NGENF
Market: OTC
Website: nervgen.com
Menu
NGENF NGENF Quote NGENF Short NGENF News NGENF Articles NGENF Message Board
Get NGENF Alerts

News, Short Squeeze, Breakout and More Instantly...
NGENF - Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.

Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF). The full research publication can be found on our website at www.encodelp.com , or by clicking here . Encode Ideas, L.P., a healthcare focused ...
NGENF - NervGen Pharma Presenting at the H.C. Wainwright 23rd Annual Global Investment Conference

Vancouver, British Columbia--(Newsfile Corp. - September 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at ...

NGENF - NervGen Pharma Announces Results of Annual General Meeting of Shareholders

Vancouver, British Columbia--(Newsfile Corp. - September 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announces the res...

NGENF - NervGen Pharma Provides an Operational Update on Its Ongoing Phase 1 Clinical Trial and Reports Second Quarter 2021 Results

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an upd...
NGENF - NervGen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer's Disease

Dr. Ksenia Kastanenka to Study NVG-291's Potential to Promote Repair in Alzheimer's Disease Models Vancouver, British Columbia--(Newsfile Corp. - August 9, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to cr...

NGENF - NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board

NervGen Supports World Brain Day on July 22 to "Stop Multiple Sclerosis" Vancouver, British Columbia--(Newsfile Corp. - July 15, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions...

NGENF - NervGen Pharma Expands Alzheimer's Disease Scientific Advisory Board

Vancouver, British Columbia--(Newsfile Corp. - July 12, 2021) -   NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the add...
NGENF - NervGen Engages Vorticom Inc. to Provide Media Relations Services

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced that it has engag...

NGENF - NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models

NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer's Disease Vancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solu...

NGENF - NervGen Pharma Reports First Quarter 2021 Results

Vancouver, British Columbia--(Newsfile Corp. - May 20, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company "), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its finan...
Previous 10 Next 10